Brachytherapy treatment by use of I-131 oral solution and now treated with I-131 capsules, reducing the dose burden to the personnel. Other brachytherapy treatments like cervical cancer and esophagus by use of Ir-192 High Dose Rate (HDR) after-loading systems are also available in four institutions. Recent advances of Prostate cancer treatment by LDR I-125 Permanent Seed Implants started at TNH in January/2017 and the relevant patients can now access the service.

We have appreciated increase in the number of prostate cancer patients reaching out for treatment by I-125 Permanent seed implants. When combined with EBRT, the brachytherapy treatment is a boost to better management of the prostate cancer patients. The number of treatment seeds can now be estimated in the pre-planning stage by use of the proposed equation for the Number of Seeds versus the Prostate volume realized for the 36 patients already treated.

Treatment of cancer by brachytherapy here in Kenya started in 1970’s and has now developed well in line with the development of the country. In particular, prostate cancer which is the most prevalent male cancer in Kenya, can now be treated by Ultrasound Guided Low Dose-Rate brachytherapy using I-125 Permanent Seed implants. This has tremendously improved the management of prostate cancer patients in this region and the Number of the Seed Implants can now be estimated by use of the proposed equation, y=1.2x+15, relating the Number of Seeds (y) used for treatment and the patient’s Prostate Volume (x).

Journal of medical physics and applied sciences is an international peer reviwed journal aiming to publish the most relevant and recent research works across the world. Medical Physicists will contribute to maintaining and improving the quality, safety and cost-effectiveness of healthcare services through patient-oriented activities requiring expert action, involvement or advice regarding the specification, selection, acceptance testing, commissioning, quality assurance/control and optimised clinical use of medical devices and regarding patient risks and protection from associated physical agents (e.g. x-rays, electromagnetic fields, laser light, radionuclides) including the prevention of unintended or accidental exposures; all activities will be based on current best evidence or own scientific research when the available evidence is not sufficient.

We are inviting the worldwide researchers and scholars to share their valuable research work in our journal.  We always encourage new research works under the scope of our Journal. You can submit the manuscript as an email attachment to medicalsci@scholarlymed.com or through online at https://www.imedpub.com/submissions/insights-medical-physics.html

Media contact

Eliza Miller

Managing Editor

Journal of Medical Physics and Applied Sciences